J. John Sperzel's Insider Trades & SAST Disclosures
J. John Sperzel's most recent trade in T2 Biosystems Inc was a trade of 490,000 Restricted Stock Units done . Disclosure was reported to the exchange on Nov. 4, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern J. John Sperzel.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| T2 Biosystems Inc | J. John Sperzel | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 490,000 | 490,000 | - | - | Restricted Stock Units | |
| T2 Biosystems Inc | Sperzel John J. | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 490,000 | 490,000 | - | - | Restricted Stock Units | |
| T2 Biosystems Inc | John J. Sperzel | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2024 | 67 | 400 (0%) | 0% | - | Common Stock | |
| T2 Biosystems Inc | John J. Sperzel | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2024 | 67 | 0 | - | - | Restricted Stock Units | |
| T2 Biosystems Inc | John Sperzel J. | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 160 | 160 | - | - | Restricted Stock Units | |
| T2 Biosystems Inc | J. Sperzel John | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 160 | 333 (0%) | 0% | - | Common Stock | |
| T2 Biosystems Inc | John J. Sperzel | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2023 | 16,000 | 32,000 | - | - | Restricted Stock Units | |
| T2 Biosystems Inc | John J. Sperzel | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2023 | 16,000 | 20,435 (0%) | 0% | - | Common Stock | |
| T2 Biosystems Inc | John J. Sperzel | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 0.65 per share. | 20 Feb 2023 | 6,875 | 13,560 (0%) | 0% | 0.7 | 4,469 | Common Stock |
| T2 Biosystems Inc | John J. Sperzel | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2023 | 6,667 | 20,227 (0%) | 0% | - | Common Stock | |
| T2 Biosystems Inc | John J. Sperzel | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2023 | 6,667 | 6,667 | - | - | Restricted Stock Units | |
| T2 Biosystems Inc | John J. Sperzel | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 0.59 per share. | 20 Feb 2023 | 2,898 | 17,329 (0%) | 0% | 0.6 | 1,710 | Common Stock |
| T2 Biosystems Inc | John J. Sperzel | Director, Chairman, CEO, and President | Purchase of securities on an exchange or from another person at price $ 0.50 per share. | 07 Apr 2022 | 30,000 | 221,773 (0%) | 0% | 0.5 | 15,000 | Common Stock |
| T2 Biosystems Inc | John J. Sperzel | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2022 | 333,333 | 333,333 (0%) | 0% | - | Common Stock | |
| T2 Biosystems Inc | John J. Sperzel | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2022 | 333,333 | 666,667 | - | - | Restricted Stock Units | |
| T2 Biosystems Inc | John J. Sperzel | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.45 per share. | 24 Feb 2022 | 141,560 | 191,773 (0%) | 0% | 0.4 | 63,532 | Common Stock |
| T2 Biosystems Inc | John J. Sperzel | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2022 | 2,400,000 | 2,400,000 | - | - | Restricted Stock Units | |
| T2 Biosystems Inc | John J. Sperzel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 1,000,000 | 1,000,000 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges